Adlai Nortye

ANL

Market cap $665M

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA.